Hanmi Pharmaceutical: This Korean Pharma Giant's Stock Could Rebound More than 50%.
Hanmi Pharm Co Ltd (128940 KS)Â stock has fallen from recent highs after Boehringer pulled out of an oncology deal and short-sellers piled on the...
806 Views
Pass on the Deal, Put on the Watchlist
This Insight finalizes our view of the listing of Samsung BioLogics (SB) using information presented at the company’s roadshow meeting and included...
408 Views
Roche's Tecentriq Approved As Second-Line in Lung Cancer: Implications For Bristol-Myers Squibb
FDA approved Roche's (U.S. ADR, OTCBB: RHHBY) Tecentriq, a checkpoint inhibitor that targets PD-L1 as a second-line therapy in metastatic non-small...
344 Views
The Chickens Are Ready to Roost
Several recent developments confirm our thesis that Inflectra's US sales in 2017 will fall far short of management's 2017 forecast. First, Pfizer's...
337 Views
Could Blue-Chip Bristol-Myers Squibb's (NYSE: BMY) Shares Rise More than 40% by Early 2018?
Bristol-Myers Squibb (NYSE: BMY) common stock is trading close to 52-week lows after the failure of pivotal phase 3 trial of Opdivo (anti-PD1...
267 Views